Analysts forecast that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will post sales of $92.72 million for the current quarter, according to Zacks. Seven analysts have made estimates for Pacira Pharmaceuticals’ earnings, with the highest sales estimate coming in at $95.00 million and the lowest estimate coming in at $89.96 million. Pacira Pharmaceuticals reported sales of $79.08 million in the same quarter last year, which would suggest a positive year over year growth rate of 17.2%. The business is expected to announce its next quarterly earnings report on Wednesday, February 27th.

On average, analysts expect that Pacira Pharmaceuticals will report full-year sales of $334.01 million for the current financial year, with estimates ranging from $332.01 million to $337.00 million. For the next financial year, analysts expect that the business will report sales of $382.49 million, with estimates ranging from $351.23 million to $395.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.40. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The firm had revenue of $83.45 million for the quarter, compared to analysts’ expectations of $79.87 million. During the same quarter in the previous year, the company earned $0.11 earnings per share. The firm’s quarterly revenue was up 23.9% compared to the same quarter last year.

Several research analysts have issued reports on PCRX shares. ValuEngine cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. Wedbush set a $90.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Monday, November 5th. Mizuho upped their price target on Pacira Pharmaceuticals to $46.00 and gave the company a “neutral” rating in a report on Monday, November 5th. JPMorgan Chase & Co. upped their price target on Pacira Pharmaceuticals from $45.00 to $50.00 and gave the company a “neutral” rating in a report on Friday, November 2nd. Finally, Jefferies Financial Group upped their price target on Pacira Pharmaceuticals to $60.00 and gave the company a “buy” rating in a report on Friday, November 2nd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $53.76.

In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 1,000 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $54.35, for a total transaction of $54,350.00. Following the transaction, the vice president now directly owns 11,474 shares in the company, valued at approximately $623,611.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO David M. Stack sold 15,000 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $47.39, for a total transaction of $710,850.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 151,221 shares of company stock worth $7,403,146. Corporate insiders own 5.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bouchey Financial Group Ltd purchased a new position in shares of Pacira Pharmaceuticals during the 3rd quarter valued at $221,000. Boston Private Wealth LLC purchased a new position in shares of Pacira Pharmaceuticals during the 3rd quarter valued at $246,000. First Republic Investment Management Inc. purchased a new position in shares of Pacira Pharmaceuticals during the 3rd quarter valued at $258,000. Parametrica Management Ltd purchased a new position in shares of Pacira Pharmaceuticals during the 3rd quarter valued at $259,000. Finally, Baird Financial Group Inc. purchased a new position in shares of Pacira Pharmaceuticals during the 3rd quarter valued at $288,000. Hedge funds and other institutional investors own 97.84% of the company’s stock.

NASDAQ:PCRX traded down $0.18 during midday trading on Monday, hitting $48.14. 404,600 shares of the stock were exchanged, compared to its average volume of 783,006. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $55.00. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of -82.97, a PEG ratio of 82.60 and a beta of 1.65. The company has a debt-to-equity ratio of 0.95, a current ratio of 8.66 and a quick ratio of 7.83.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Article: Cost of Capital

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.